An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

Conclude your understanding of lymphoma with an in-depth look at its signs and symptoms, from common indicators to subtle clues.

Speaker : Dr Suvir Singh

Cost Burden/ Burden of Hospitalization For R/R ALL Patients

Explore expert insights from Dr. Pawan Kumar Singh, Dr. Roshan Dikshit, Dr. Manisha Jain, and Dr. Avriti Baveja on the cost and hospitalization burden for R/R ALL patients.

Speakers : Dr. Pawan Kumar Singh , Dr. Manisha Jain , Dr. Roshan Dikshit , Dr. Avriti Baveja

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I

In this webinar, a detailed discussion is done on Expert group convenes to discuss management strategies for EGFR mutation-positive NSCLC.

Speakers : Dr. Vineet Govinda Gupta ( Moderator ) ,Dr. Atul Sharma ( Panelist ) ,Dr. Abhishek Bansal ( Panelist )

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III

Expert meeting discussing management strategies and therapies for EGFR mutation-positive non-small cell lung cancer.

Speakers : Dr. Abhishek Bansal ( Panelist ) ,Dr. Atul Sharma ( Panelist ) ,Dr. Vineet Govinda Gupta ( Moderator )

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV

Expert panel discusses targeted therapies and strategies for managing EGFR mutation-positive non-small cell lung cancer.

Speakers : Dr. Vineet Govinda Gupta ( Moderator ) ,Dr. Atul Sharma ( Panelist ) ,Dr. Abhishek Bansal ( Panelist )

Dacomitinib Case Presentation: Baseline Treatment and Current Status

Explore Dr. Viraj Nevrekar’s expert insights on Dacomitinib in NSCLC, covering baseline treatment approaches, efficacy, and real-world case studies.

Speakers : Dr Viraj Nevrekar- (Moderator)

Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations

Explore Dr. Viraj Nevrekar’s expert analysis on the molecular and clinical differences between EGFR Exon 19 deletion and Exon 21 L858R mutations in NSCLC.

Speakers : Dr. Viraj Nevrekar

First Line Combination Therapy- The Overall Survival Data in NSCLC Patients

Dr. Viraj Nevrekar discusses first-line combination therapy and overall survival data in NSCLC, covering immunotherapy, targeted therapy, and chemotherapy.

Speakers : Dr. Viraj Nevrekar

L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients

Explore Dr. Viraj Nevrekar’s analysis of the L858R mutation in advanced NSCLC through a retrospective cohort study, covering treatment outcomes, survival trends, and clinical outcomes

Speakers : Dr. Viraj Nevrekar

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V

In this webinar, a detailed discussion is done on CROWN trial update: Optimizing 1st-line ALK+ mNSCLC management.

Speakers : Dr Srujna Joga ( Expert Panel ) ,Dr AP Dubey ( Expert Panel ) ,Dr Atul Sharma ( Expert Panel ) ,Dr Jyoti Wadhwa ( Moderator )

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV

In this webinar, a detailed discussion is done on CROWN trial update: Optimizing 1st-line ALK+ mNSCLC management.

Speakers : Dr Srujna Joga ( Expert Panel ) ,Dr AP Dubey ( Expert Panel ) ,Dr Atul Sharma ( Expert Panel ) ,Dr Jyoti Wadhwa ( Moderator )


Recommended News For You

fresh E. Coli Outbreak: ECMO Redefining Death and Bringing Universal Blood One Step Nearer.

World's premier cancer institute faces crippling cuts and chaos

In-person and Virtual Palliative Care Are Both Beneficial for Advanced Lung Cancer Patients.

FDA Approves Hemophilia B Second Gene Therapy.

Potential new therapy for childhood brain cancer could heal treatment-resistant tumors

Mutation Clearance After Transplant Linked to Better Outcomes in Myelofibrosis

Specialized imaging improves overall prostate cancer survival by identifying benefits of salvage radiotherapy

Recommended Articles For You

Unveiling the Mystery Behind Lymphovascular Invasion 

Colon cancer: Risk factors, warning signs and treatment options  

The benefits and risks of taking fludrocortisone for adrenal insufficiency  

Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study 
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Why preventive mastectomy isn't offered to everyone at risk

2.

Financial hardship common in patients with cancer

3.

Academics + Pharma = Big Bucks; New CAR-T Warnings; Patients Seek Cancer Tests.

4.

Acalabrutinib + Venetoclax Combo Earns FDA Nod for CLL

5.

Severe obesity associated with reduced prevalence of recommended cancer screenings

1.

Sound Waves and Self-Destruction: A Promising Nanotech Weapon in the Fight Against Cancer

2.

Claudin-18.2 in Gastric Cancer: Tumor-Stroma Crosstalk and Disease Progression

3.

Real-World Oncology Insights: CAR-T, Immunotherapy, PROs, and Digital Tools

4.

Unleashing Precision Medicine: CRISPR-Cas9 Gene Editing in Hematopoietic Stem Cells

5.

Unveiling Tumor Immunity: Pan-Cancer Proteogenomics Characterization

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Current Scenario of Blood Cancer- Genomic Testing & Advancement in Diagnosis and Treatment

2.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part V

3.

From Relapse to Remission Mapping the Treatment Journey in Adult R R B Cell ALL The Critical Goal of MRD

4.

Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL

5.

Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot